This activity is supported by an educational grant from Incyte Corporation.
Oncology NPs, PAs, and nurses
Identify recommended biomarkers and tests to guide therapy for advanced CCA
Assess data from clinical trials and evidence-based guidelines to identify treatments for patients with FGFR2-rearranged CCA
Apply strategies to recognize and manage AEs of novel therapies for CCA
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Philip A. Philip, MD, PhD, FRCP: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Blueprint, Daiichi Sankyo, Erytech, Genentech, Incyte, Ipsen, Merck, Novartis, Novocure, Rafael, Seagen, TriSalus; research support: Astellas, BeiGene, Incyte, NGM Bio, Karyopharm, Novocure, QED, Rafael, Syncore, Thyme.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: May 25, 2022
Expiration date: May 24, 2023
eNewsletter with interactive benchmarking and audio commentary
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP Course Advisor: Kristen O'Hagan, MSN, ANP-BC, AOCNP, Memorial Sloan Kettering Cancer Center, Montvale, New Jersey
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until May 24, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program has been made available online.